Tachykinins and the potential causal factors for post-COVID-19 condition

SJ Janket, DD Fraser, AE Baird, F Tamimi… - The Lancet …, 2023 - thelancet.com
The most prevalent symptoms of post-COVID-19 condition are pulmonary dysfunction,
fatigue and muscle weakness, anxiety, anosmia, dysgeusia, headaches, difficulty in …

Substance P and Prokineticin-2 are overexpressed in olfactory neurons and play differential roles in persons with persistent post-COVID-19 olfactory dysfunction

T Schirinzi, R Lattanzi, D Maftei, P Grillo… - Brain, Behavior, and …, 2023 - Elsevier
Persistent olfactory dysfunction (OD) is one of the most complaining and worrying
complications of long COVID-19 because of the potential long-term neurological …

A scoping review of pharmacological management of postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection in 2021

E Carson, AN Hemenway - American journal of therapeutics, 2022 - journals.lww.com
Background: Postacute sequelae of severe acute respiratory syndrome coronavirus 2
infection (PASC), or long-COVID, are signs and symptoms that persist after the acute phase …

Systematic down-selection of repurposed drug candidates for COVID-19

CA MacRaild, MUR Mohammed, Faheem… - International journal of …, 2022 - mdpi.com
SARS-CoV-2 is the cause of the COVID-19 pandemic which has claimed more than 6.5
million lives worldwide, devastating the economy and overwhelming healthcare systems …

[PDF][PDF] Faheem

C MacRaild, M Muzaffar-Ur-Rehman - Murugesan, S - academia.edu
SARS-CoV-2 is the cause of the COVID-19 pandemic which has claimed more than 6.5
million lives worldwide, devastating the economy and overwhelming healthcare systems …

Advances in the research and application of neurokinin-1 receptor antagonists

X Hong, J Ma, S Zheng, G Zhao, C Fu - Journal of Zhejiang University …, 2024 - Springer
Recently, the substance P (SP)/neurokinin-1 receptor (NK-1R) system has been found to be
involved in various human pathophysiological disorders including the symptoms of …

神经激肽1 受体拮抗剂的研究与应用进展

洪翔宇, 马俊杰, 郑珊珊, 赵光宇… - 浙江大学学报(英文版)(B …, 2024 - jzusb.zjujournals.com
目前研究已经发现神经肽(SP)/神经激肽1 受体(NK-1R) 拮抗剂系统参与了包括2019
冠状病毒病(COVID-19) 症状在内的多种人体生理疾病. 肿瘤学领域的最新研究表明: NK-1R …